It’s exciting to watch our partners at Horizon Therapeutics grow. The company’s new $3.1 billion purchase of a Maryland-based drug maker is a tremendous boost to an already-robust portfolio of rare disease treatments.
< BACK TO MAIN NEWS PAGE
It’s exciting to watch our partners at Horizon Therapeutics grow. The company’s new $3.1 billion purchase of a Maryland-based drug maker is a tremendous boost to an already-robust portfolio of rare disease treatments.